Navigation Links
Aushon BioSystems Appoints Martin Verhoef Chief Executive Officer

BILLERICA, Mass., Sept. 4, 2012 /PRNewswire/ -- Aushon BioSystems today announced that Martin Verhoef has been appointed Chief Executive Officer.  Mr. Verhoef has also been appointed to the Company's Board of Directors. Peter Honkanen, Founder and former Chief Executive Officer, will assume the Chief Operating Officer role and continue as a Board Director.


"We welcome Martin to Aushon and are especially excited about the extensive commercialization experience he brings to the organization.  Now that the company has achieved its product development milestones, it's sharpening its focus on the commercialization of its products.  With his background and experience, Martin offers the right leadership to realize the company's potential," commented Rich D'Amore, Founding Partner of North Bridge Venture Partners.

"I'm very excited to work with Martin and to shift my focus to further strengthening the Development and Operations teams as we prepare the organization for substantial growth," added Peter Honkanen.

Mr. Verhoef has a career of over 25 years experience in the life science research tools and molecular diagnostics business.  Prior to joining Aushon, Mr. Verhoef was Chief Executive Officer at the molecular diagnostic firms MiraDx and PrimeraDx. He was also a member of Ciphergen's executive team where he led the company's BioSystems Division. Mr. Verhoef has also held various senior management roles at Agilent in Germany and the US.  He holds BS degrees in Medical Chemistry and Chemistry from the van 't Hoff Institute in Rotterdam, The Netherlands.

"I am delighted to be joining Aushon at this stage of its development. The new Cira™ platform has been exceptionally well received and is already being adopted by key customers throughout the life science industry. I strongly believe that CiraPlex™ will become the platform of choice for protein biomarker analysis and will help drive personalized medicine," commented Mr. Verhoef.

About Aushon

Aushon BioSystems, Inc., provides a comprehensive suite of multiplex immunoassay products and services for protein biomarker discovery, development, and analysis to leading pharmaceutical, biotechnology, academic, and diagnostic clients worldwide. Our unique combination of proprietary microarray printing, extensive biomarker content, and our innovative Cira immunoassay platform deliver exceptional performance, quality, and reliability to accelerate preclinical and clinical biomarker research. Our customers, who include nine of the top ten pharmaceutical companies, trust Aushon to supply the most reliable biomarker data available, lowering costs and improving research productivity.

Aushon Contact:

Rocco Raduazo

Vice President, Sales & Marketing

SOURCE Aushon BioSystems
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ahram Biosystems Announces Launch of the New Economy Model F1-12 of Its Palm PCR Series
2. BioNeutral Group Appoints Mr. Mark Lowenthal as Chief Executive and President
3. BioNeutral Group Appoints A New Member to the Board of Directors
4. Western Carolina University, College of Business Appoints New Director of Entrepreneurship and Innovation
5. JG Finneran Associates Appoints Chebios as its Exclusive Distributor in Italy
6. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
7. ViaCyte Appoints Dr. Paul Laikind Chief Executive Officer
8. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Regulus Therapeutics Appoints Bruce Carter to its Board of Directors
11. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... 23, 2016 Andrew ... Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... San Francisco, CA (PRWEB) , ... June 23, ... ... capture (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase ... DIA Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
Breaking Biology Technology:
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):